This study investigates the efficacy of modified Albizia procera gum as a release-retardant polymer in Diltiazem hydrochloride (DIL) matrix tablets. Carboxymethylated Albizia procera gum (CAP) and ionically crosslinked carboxymethylated Albizia procera gum (Ca-CAP) were utilized, with Ca-CAP synthesized via crosslinking CAP with calcium ions (Ca₂₊) using calcium chloride (CaCl₂). FTIR analysis affirmed polymer compatibility, while Differential scanning calorimetry (DSC) and X-ray diffraction (XRD) assessed thermal behavior and crystallinity, respectively. Zeta potential analysis explored surface charge and electrostatic interactions, while rheology examined flow and viscoelastic properties. Swelling and erosion kinetics provided insights into water penetration and stability. CAP's carboxymethyl groups (-CH2-COO^-) heightened divalent cation reactivity, and crosslinking with CaCl₂ produced Ca-CAP through -CH2-COO^- and Ca₂₊ interactions. Structural similarities between the polymers were revealed by FTIR, with slight differences. DSC indicated modified thermal behavior in Ca-CAP, while Zeta potential analysis showcased negative charges, with Ca-CAP exhibiting lower negativity. XRD highlighted increased crystallinity in Ca-CAP due to calcium crosslinking. Minimal impact on RBC properties was observed with both polymers compared to the positive control as water for injection (WFI). Ca-CAP exhibited improved viscosity, strength, controlled swelling, and erosion, allowing prolonged drug release compared to CAP. Stability studies confirmed consistent six-month drug release, emphasizing Ca-CAP's potential as a stable, sustained drug delivery system over CAP. Robustness and accelerated stability tests supported these findings, underscoring the promise of Ca-CAP in controlled drug release applications.

本研究研究了改性合欢树胶作为缓释聚合物在盐酸地尔硫卓 (DIL) 骨架片中的功效。使用羧甲基化合欢胶(CAP)和离子交联羧甲基化合欢胶(Ca-CAP)，其中使用氯化钙(CaCl _{2 )将CAP与钙离子(Ca 2+} )交联合成Ca-CAP 。 FTIR 分析证实了聚合物的相容性，而差示扫描量热法 (DSC) 和 X 射线衍射 (XRD) 分别评估了热行为和结晶度。 Zeta 电位分析探索表面电荷和静电相互作用，而流变学则研究流动和粘弹性。膨胀和侵蚀动力学提供了对水渗透和稳定性的见解。 CAP的羧甲基基团(-CH2-COO ^- )提高了二价阳离子的反应性，并通过-CH2-COO ^-和Ca _{2+相互作用与CaCl 2}交联产生Ca-CAP 。 FTIR 显示聚合物之间的结构相似，但略有差异。 DSC 表明 Ca-CAP 的热行为发生了变化，而 Zeta 电位分析显示出负电荷，其中 Ca-CAP 表现出较低的负电荷。 XRD 强调了由于钙交联导致 Ca-CAP 结晶度增加。与注射用水 (WFI) 等阳性对照相比，两种聚合物对红细胞特性的影响最小。与 CAP 相比，Ca-CAP 表现出改善的粘度、强度、可控的膨胀和侵蚀，可延长药物释放时间。稳定性研究证实了六个月药物释放的一致性，强调了 Ca-CAP 作为 CAP 稳定、持续药物输送系统的潜力。稳健性和加速稳定性测试支持了这些发现，强调了 Ca-CAP 在受控药物释放应用中的前景。